Skip to main content

Need Immediate Care?

Find Urgent Care Locations

Cabazitaxel with or Without Carboplatin in Patients with Metastatic Castrate-Resistant Prostate Cancer (mCRPC), Stratified by Aggressive Variant Signature (CARAVAN)

Short Title: S2312


Enrollment Status: Recruiting

NCT #: NCT06470243

Specialty Area: Oncology

Condition Studied: Metastatic Castrate-Resistant Prostate Cancer

Age Groups: Adult; Older Adult

Phase: III


Study Information

Summary / Purpose

This study is looking at the best way to treat prostate cancer that has spread to other parts of the body and that keeps growing even when testosterone is lowered to very low levels. Doctors call this metastatic castrate-resistant prostate cancer, or mCRPC.

Cabazitaxel is a chemotherapy drug that is already used as standard care for this type of cancer. Researchers want to find out whether adding a second chemotherapy drug, carboplatin, works better than cabazitaxel on its own. Participants receive either cabazitaxel alone or cabazitaxel together with carboplatin.

Some prostate cancers carry a set of genetic changes known as an aggressive variant signature. Tumor tissue is tested before treatment is assigned so that results can be compared between people who have this signature and people who do not. This may help doctors learn which treatment approach fits which type of cancer.

This is a phase III treatment study, which means the drugs have already been studied in smaller groups of people. Taking part may or may not help your own cancer. The main goal is to answer a question that could guide care for future patients.

Study Type: Interventional
Accepts Healthy Volunteers: No

Who Can Participate

Eligibility Criteria:

This study is enrolling men who are being treated for prostate cancer that has spread. It is not enrolling healthy volunteers. The summary below describes the general requirements in everyday language.

You may be able to join if...

  • You are male and 18 years of age or older
  • You have a confirmed diagnosis of metastatic prostate adenocarcinoma
  • Your cancer continues to grow even though your testosterone level is very low (castrate-resistant)
  • You have measurable disease that can be followed on scans
  • You have progressive disease, meaning tests show the cancer is getting worse
  • You have tumor tissue from an earlier biopsy that can be sent for central testing, or your team can obtain a sample
  • Your blood counts, kidney function, and liver function are within the range the study requires
  • You are well enough to carry out most daily activities

You may not be able to join if...

  • You have already been treated with cabazitaxel or carboplatin
  • You have had other chemotherapy for metastatic castrate-resistant prostate cancer that the study team decides would interfere
  • You have significant numbness, tingling, or pain in your hands or feet (neuropathy)
  • You have another serious medical condition that is not under control, such as an active infection or uncontrolled heart problems
  • You are taking part in another treatment study that would conflict with this one

This is not a complete list of requirements. The study team reviews your medical history, exam, and test results with you and confirms whether this trial is a good fit.

What's Involved

Participation in the study will include:

Before anything is decided, tumor tissue from an earlier biopsy is sent to a central laboratory to check for the aggressive variant signature. A chest X-ray and other baseline tests are also done to confirm you can take part.

Participants are then randomly assigned by computer to one of two treatment groups. Neither you nor your doctor chooses the group. One group receives cabazitaxel given through a vein (IV). The other group receives IV cabazitaxel together with IV carboplatin. Everyone takes prednisone by mouth twice a day.

What to expect during the study

  1. Submit tumor tissue from a previous biopsy for central testing before treatment is assigned
  2. Have baseline tests, including a chest X-ray and blood work
  3. Be randomly assigned to cabazitaxel alone or cabazitaxel plus carboplatin
  4. Come to the clinic for IV infusions on a repeating cycle schedule and take prednisone by mouth at home
  5. Have regular blood samples collected to check how your body is handling treatment
  6. Have imaging such as bone scans, CT scans, PET scans, or MRI scans to see how the cancer responds

Visits continue on the cycle schedule for as long as treatment is helping and side effects stay manageable. After treatment ends, the study team keeps in touch for follow-up visits and phone calls to check on your health and record how you are doing over time.

Taking part is voluntary. You can decide not to join, or you can stop at any point, and your regular medical care will not be affected.

Principal Investigator

Additional Information

Location: Renown Health, Office of Clinical Research
Address:

1500 E 2nd St. Reno, NV 89502

General Research: 775-982-3646
Oncology Research: 775-982-5050
Email: Renown-CRD@renown.org

Disclaimer: This listing gives you general information about the study and isn't part of the official consent process. If you decide to learn more, the research team will talk with you and check if you meet any additional requirements to join the study.

ER Wait Times

How are wait times calculated?

Our estimated ER wait times reflect the average time from check-in to being seen by a medical professional during triage, where patients are prioritized based on the severity of their condition.